Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
Australia’s Therapeutic Goods Administration (TGA) has accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty (YSCP), regarding advertising of prescription-only compounded medicines for weight-loss. 7 April 2025
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors.
Latest News & Features of interest to Novo Nordisk
Pharmaceutical
US biopharma Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase III TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity. 8 April 2025
Pharmaceutical
At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in development for early PD, failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy. 8 April 2025
Biosimilars
Israel-based Teva Pharmaceuticals industries today revealed two important updates reflecting its commitment to expanding access to both biosimilars and innovative medicines. 7 April 2025
Pharmaceutical
Alzheon, a privately-held clinical-stage biopharma company, presented promising Phase III APOLLOE4 trial results for ALZ-801 (valiltramiprosate) in treating mild cognitive impairment (MCI) in APOE4 homozygous patients at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (PD). 7 April 2025
Biotechnology
South Korean clinical-stage biotech ABL Bio on Sunday announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. 7 April 2025
Biotechnology
The European Commission (EC) has approved an indication extension of Darzalex (daratumumab) subcutaneous (SC) formulation in the frontline setting. 7 April 2025
Pharmaceutical
Australia’s Therapeutic Goods Administration (TGA) has accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty (YSCP), regarding advertising of prescription-only compounded medicines for weight-loss. 7 April 2025
Pharmaceutical
In the news last week, US Center for Biologics Evaluation and Research (CBER) Dr Peter Marks quit his post after reported pressure from a Human Health Services (HHS) official. On the research front, Merck & Co presented positive Phase III data on its Winrevair in pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) meeting. Also, Swiss biotech AC Immune shared new Phase II data on its Parkinson’s disease candidate ACI-7104-056. Late last Wednesday, US President Donald Trump dropped a bombshell of tariffs of various amounts on countries around the world, although there was ambiguity as to how and when they would impact pharma and biotech products. 6 April 2025
Pharmaceutical
al rule on April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) programs.
New Medicare proposals will not cover obesity drugs
April 4, 2025 5 April 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Latest In Brief for Novo Nordisk
Latest Related Ones To Watch News
Japanese drugmaker Otsuka Holdings’ subsidiary Taiho Pharmaceuticals is to buy Araris Biotech, a Swiss oncology firm developing antibody drug conjugates (ADCs). 17 March 2025
11 March 2025
11 February 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze